Welcome to our dedicated page for Applied Dna Scie news (Ticker: APDN), a resource for investors and traders seeking the latest updates and insights on Applied Dna Scie stock.
Applied DNA Sciences, Inc. (APDN) delivers innovative synthetic DNA solutions for therapeutic development, molecular diagnostics, and supply chain security. This news hub provides investors and industry professionals with centralized access to official corporate announcements and verified updates.
Track critical developments across the company's core operations, including advancements in PCR-based DNA production, diagnostic testing services, and anti-counterfeiting technologies. Our curated feed features earnings reports, strategic partnerships, product launches, and regulatory milestones that impact APDN's market position.
Key focus areas include updates on the Linea DNA platform for mRNA therapeutics, CertainT forensic authentication solutions, and clinical testing services. Users benefit from timestamped press releases organized chronologically while maintaining factual accuracy and regulatory compliance.
Bookmark this page for direct access to Applied DNA Sciences' latest financial disclosures, technology patents, and supply chain security initiatives. Check regularly for updates on nucleic acid manufacturing innovations and DNA-based brand protection programs shaping the biotechnology sector.
Applied DNA Sciences (NASDAQ:APDN) has issued a reminder to shareholders to cast their votes before the reconvening of a Special Meeting of Stockholders scheduled for February 14, 2025, at 11:00 a.m. The meeting, originally held on January 23, 2025, was adjourned due to lack of quorum.
The primary focus is the Warrant Exercise Proposal, which seeks approval for the exercisability of certain common stock purchase warrants and the issuance of underlying common stock. These warrants were issued during a securities offering on October 30, 2024. Shareholders of record as of November 25, 2024, who haven't yet voted can contact Kingsdale Advisors at 1-855-682-9644 or contactus@kingsdaleadvisors.com.
The proposal requires approval in accordance with Nasdaq Listing Rule 5635(d), as detailed in the Company's definitive proxy statement filed with the SEC on December 10, 2024.
Applied DNA Sciences (NASDAQ:APDN) has completed the buildout of its new Good Manufacturing Practices (GMP) facility at its Stony Brook, New York headquarters. The facility, expected to be fully operational by January's end, will manufacture LineaDNA IVT templates for mRNA clinical trial materials.
Key facility specifications include:
- Annual IVT template manufacturing capacity of ~10 grams with 100% cell-free workflow
- 10mg to gram-scale production in 6-14 weeks
- Projected revenue capacity of $10-30 million depending on product mix
- Multiple purification options and dedicated quality control areas
The company is currently negotiating a supply agreement for GMP IVT template with an mRNA therapeutic developer and reaffirmed its plan to complete strategic restructuring by quarter-end to drive sustainable growth, optimize costs, and extend cash runway.
Applied DNA Sciences (NASDAQ:APDN) has announced the rescheduling of its Investor Update call from January 9, 2025, to Thursday, February 13, 2025. The rescheduling aligns with the release of the company's first quarter fiscal 2025 financial results. The original call was intended to provide shareholders with updates on the company's strategic restructuring announced in December 2024 and GMP initiative. The schedule change is due to the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.
Applied DNA Sciences (NASDAQ:APDN) announced that the Czech Republic's State Institute for Drug Control approved a Phase I clinical trial for UHKT-CAR123-01, a CD123-specific autologous CAR T-cell therapy using Applied DNA's Linea DNA technology. The trial, conducted by the Institute of Hematology and Blood Transfusion (ÚHKT) in Prague, targets relapsed and/or refractory acute myeloid leukemia (AML).
The therapy aims to address high costs and long manufacturing times associated with traditional viral vector-based CAR T-cell therapies. Preclinical data demonstrated that ÚHKT's non-viral workflow using Linea DNA achieved rapid production of CAR T-cells with high potency while reducing manufacturing costs and timelines.
Applied DNA Sciences (NASDAQ:APDN) announced strategic restructuring to focus on manufacturing critical starting materials for genetic medicines. The company plans to divest its CertainT® platform and targets 15% operating expense reduction by Q2 FY2025. The company's GMP manufacturing facility is expected to be completed by January 9, 2025, with projected annual revenue capacity between $4-16 million.
Q4 FY2024 financial results showed revenues of $813,000 (up from $780,000 in Q4 FY2023), with an operating loss of $3.3 million (improved from $4.2 million). FY2024 total revenues were $3.4 million, down from $13.4 million in FY2023. Cash position was $6.4 million as of September 30, 2024, with additional $5.8 million raised through an October offering.
Applied DNA Sciences (NASDAQ:APDN) announced it will release its fourth quarter and fiscal year 2024 financial results after market close on December 17, 2024. The company will host a conference call and webcast for investors on January 9, 2025, at 4:30 p.m. ET, which will include an update on its GMP manufacturing facility build-out. The presentation will be accessible via webcast and conference call, with replay options available for 7 days following the event. An accompanying slide presentation will be available on the company's investor relations website.
Applied DNA Sciences (NASDAQ:APDN) has announced the pricing of a $6.5 million registered direct offering and concurrent private placement. The offering includes 20,312,500 shares at $0.32 per share, along with Series C and Series D Warrants. The Series C Warrants expire in 5 years and Series D Warrants in 18 months after stockholder approval, both with an exercise price of $0.32. The company plans to use proceeds for developing Therapeutic DNA Production Services and general corporate purposes. The offering is expected to close around October 31, 2024, with Craig-Hallum acting as exclusive placement agent.
Applied DNA Sciences, Inc. (NASDAQ:APDN) has announced its participation in the 2024 Maxim Healthcare Virtual Summit. The company's president and CEO, Dr. James A. Hayward, will engage in a fireside chat on Wednesday, October 16, 2024, at 12:50 p.m. EDT. This virtual event, hosted by Maxim Group , runs from October 15th to 17th.
The interview will be conducted by Jason McCarthy, Ph.D., Maxim's senior managing director and head of Biotechnology Research. Registered conference attendees will have access to view Applied DNA's fireside chat. Applied DNA, known for its leadership in PCR-based DNA technologies, will use this platform to share insights with the healthcare investment community.
Applied DNA Sciences, Inc. (NASDAQ:APDN) has regained compliance with Nasdaq's minimum bid price requirement. The company received a notification letter on September 17, 2024, confirming that its common stock maintained a closing bid price of $1.00 or higher for 20 consecutive business days from August 19 to September 16, 2024. This development resolves the previous non-compliance issue reported on July 12, 2024, when APDN's stock failed to maintain the required minimum bid price. Nasdaq now considers this matter closed, ensuring Applied DNA's continued listing on the exchange.
Applied DNA Sciences (NASDAQ:APDN) announced its participation in the 3rd Annual mRNA Process Development & Manufacturing Summit in Boston from September 17-19, 2024. The company will showcase its Linea™ IVT platform, a solution for faster and better mRNA production with reduced double-stranded RNA contamination.
LineaRx, a majority-owned Applied DNA company, will present the platform, which combines an enzymatically produced DNA template with a next-generation RNA polymerase. Additionally, LineaRx and mRNA CDMO partner Kudo Biotechnology will co-host a seminar luncheon on September 19 to present data demonstrating Linea IVT's capability for rapid manufacturing of dsRNA-mitigated mRNA.
FAQ
What is the current stock price of Applied Dna Scie (APDN)?
What is the market cap of Applied Dna Scie (APDN)?
